Developing Human STING Inhibitor Assets
Discovering a better future
IFNRx is focused on the development of stimulator of interferon genes (STING) protein inhibitors, targeting Parkinson's disease (PD) and related neuroinflammatory disorders.
Our research also extends to similar neuroinflammatory diseases, such as Alzheimer's disease, ALS and long COVID-19 disorder, each representing significant market opportunities.
With such neuro-related diseases affecting over 50 million people globally, we are tapping into a projected $50B marketplace.
Our Team
Led by a group of seasoned researchers, our team's diverse expertise spans medicinal chemistry, immunology, pharmacology and clinical research. We are committed to innovation and excellence, driven by a passion to make a tangible difference in the lives of those affected by neuroinflammatory and neurodegenerative diseases. Collaboration is at our core and we take pride in working alongside leading scientists, clinicians and a patient advocacy groups to advance our research and development efforts.
IFNRx-H
STING inhibitor hit-to-lead IFNRx-H chemotype compounds were identified with previous funding from the NIH and the Michael J. Fox Foundation.
Lead compound IFNRx-H001 significantly attenuates both STING activation and function in vitro and exhibits blood-brain barrier (BBB) permeability in vivo following a single oral dose.
In silico 3D models of STING protein predict that IFNRx-H001 binds to the cGAMP binding pocket.